



ViSci (Subsidiary) : Approval to register an additional patent in Europe

Tel Aviv (March 14, 2019) – BioLight is pleased to announce that today, its subsidiary ViSci Ltd., ("**ViSci**")¹, announced it has received approval to register a patent from the European Patent Office (the "**Patent**").

The Patent, which joins patent families protecting ViSci 's Eye-D technology, and its first indication, the VS-101, which is an intraocular implant for controlled and delayed release for the treatment of glaucoma using latanoprost, (the "**Device**" and "**ViSci's Product**") protects the Device that is designed for localized sustained release of API, in particularly sub-conjunctively, for the treatment of glaucoma and is intended to strengthen and thicken the protection of the ViSci's product.

The Device, which is in its development and licensing stages for treating glaucoma, is based on technology for which ViSci received an exclusive, worldwide, perpetual license from Novartis LLC. The expiration date of the Patent, after its registration, is on May 17, 2031.

The aforementioned approval in Europe which protects the structure of the Device joins an additional patent approval that was received by the European Patent Office on July 2018 and protects the chemical structure of the family of the active ingredient for the treatment of glaucoma in ViSci's product as well as a patent parallel to technology in the United States, including other patents in the United States related to said technology and the Device - and are protected under said ViSci's exclusive license, thereby strengthening its intellectual property and competitive position. The completion of registration of the Patent is subject to the payment of the fee, as customary.

¹ Holding via XL Vision Sciences Ltd., 97% of the issued and share capital of ViSci.

